8:00-8:30
Light Breakfast
Targeted Mass Spectrometry Assays for Diabetes and Obesity Research (TaMADOR)
May 14 @ 8:30 am - 4:10 pm
Free8:30-8:40
Salvatore Sechi, PhD
NIDDK/NIH
History and Purpose of TaMADOR
8:40-8:50
Will Cefalu, M.D.
NIDDK/NIH
Welcome and Introduction (Virtual)
8:50-9:30
Lori Sussel, Ph.D.
University of Colorado Anschutz Medical Campus
Paradoxically: Using proteomics to study non-coding RNAs
9:30-9:55
Mike MacCoss, Ph.D.
University of Washington School of Medicine
Alterations in the plasma extracellular proteome due to treatment of type 1 diabetes
9:55-10:20
Wei-Jun Qian, Ph.D.
Pacific Northwest National Laboratory
Single-islet proteomics maps pseudo-temporal Islet Immune responses and dysfunction in stage 1 T1D
10:20-10:30
Coffee Break
10:30-11:10
Joe Hedrick, Ph.D.
C-PATH Institute
Surrogate endpoint biomarkers for T1D interventions: a regulatory perspective
11:10-11:35
Jessica Becker, MLS(ASCP), M.S.
University of Washington School of Medicine
Interlaboratory validation of an LC-MS/MS assay for glucagon and oxyntomodulin
11:35-12:00
Lorenz Nierves, Ph.D.
Pacific Northwest National Laboratory
MS-based simultaneous quantification of proinsulin and proglucagon processing products to investigate processing mechanisms
12:00-12:45
Lunch
12:45-1:25
Emily Sims, M.D.
Indiana University School of Medicine
Clinical Applications of Prohormone Ratios in Type 1 Diabetes
1:25-1:50
Andy Hoofnagle, MD Ph.D.
University of Washington School of Medicine
Quantification of proinsulin by proteolysis-aided-peptide immunoenrichment-LC-MS/MS
1:50-2:15
Jun Qu, Ph.D.
University of Buffalo
Cross-laboratory validation of a multiplexed LC-MS/MS assay for intact proinsulin, des-31,32/des-64,65 proinsulin, and C-peptide
2:15-2:30
Coffee Break
2:30-2:55
Wei-Jun Qian, Ph.D.
Pacific Northwest National Laboratory
Assessment of intact, des-31,32, and des-64,65 proinsulin as potential biomarkers in cross-sectional and longitudinal samples following T1D diagnosis
2:55-3:20
Sara Shijo, B.S.
University of Washington School of Medicine
Development of proglucagon assays
3:20-4:00
Steven Kahn, M.B., Ch.B.
University of Washington School of Medicine
(1) Beta-cell Peptides: It Does Not Stop With Insulin and C-peptide (2) Taking New Assays Into the “Real World”: Working With the Diabetes Research Centers
4:00-4:20
Panel Discussion: Kuanysh Kabytaev, Des Schatz, Emily Sims, Andy Hoofnagle
C-peptide: Harmonization, clinical utility, and reimbursement requirements
